Active Ingredient(s):Vemurafenib FDA Approved: * August 17, 2011 Pharm Company: *HOFFMAN-LA ROCHE Category:Cancer
Vemurafenib (INN, marketed as Zelboraf) is an inhibitor of the B-Raf enzyme developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma. The name "vemurafenib" comes from V600E mutated BRAF inhibition.
2 Mechanism of action
3 Clinical trials
3.1 Side effects
5 Further reading
6 External links
Vemurafenib received FDA approval for the treatment of late-stage...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion